These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

599 related articles for article (PubMed ID: 25917418)

  • 21. Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity.
    Ferrari S; Mercuri M; Rosito P; Mancini A; Barbieri E; Longhi A; Rimondini S; Cesari M; Ruggieri P; Di Liddo M; Bacci G
    J Chemother; 1998 Dec; 10(6):484-91. PubMed ID: 9876058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Etoposide and carbo-or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: a large retrospective study.
    van Maldegem AM; Benson C; Rutkowski P; Blay JY; van den Berg H; Placzke J; Rasper M; Judson I; Juergens H; Dirksen U; Gelderblom H
    Pediatr Blood Cancer; 2015 Jan; 62(1):40-4. PubMed ID: 25251256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial.
    Le Deley MC; Paulussen M; Lewis I; Brennan B; Ranft A; Whelan J; Le Teuff G; Michon J; Ladenstein R; Marec-Bérard P; van den Berg H; Hjorth L; Wheatley K; Judson I; Juergens H; Craft A; Oberlin O; Dirksen U
    J Clin Oncol; 2014 Aug; 32(23):2440-8. PubMed ID: 24982464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multimodal treatment including standard chemotherapy with vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for the Ewing sarcoma family of tumors in Japan: Results of the Japan Ewing Sarcoma Study 04.
    Chin M; Yokoyama R; Sumi M; Okita H; Kawai A; Hosono A; Koga Y; Sano H; Watanabe H; Ozaki T; Mugishima H;
    Pediatr Blood Cancer; 2020 May; 67(5):e28194. PubMed ID: 32077253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group.
    Womer RB; West DC; Krailo MD; Dickman PS; Pawel BR; Grier HE; Marcus K; Sailer S; Healey JH; Dormans JP; Weiss AR
    J Clin Oncol; 2012 Nov; 30(33):4148-54. PubMed ID: 23091096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Developing a prognostic model for localized Ewing sarcoma family of tumors: A single institutional experience of 224 cases treated with uniform chemotherapy protocol.
    Biswas B; Rastogi S; Khan SA; Shukla NK; Deo SV; Agarwala S; Mohanti BK; Sharma MC; Vishnubhatla S; Bakhshi S
    J Surg Oncol; 2015 May; 111(6):683-9. PubMed ID: 25557999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
    Grier HE; Krailo MD; Tarbell NJ; Link MP; Fryer CJ; Pritchard DJ; Gebhardt MC; Dickman PS; Perlman EJ; Meyers PA; Donaldson SS; Moore S; Rausen AR; Vietti TJ; Miser JS
    N Engl J Med; 2003 Feb; 348(8):694-701. PubMed ID: 12594313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Challenges in the management of localized Ewing sarcoma in a developing country.
    Totadri S; Bansal D; Rao KLN; Jain R; Saxena AK; Kapoor R; Samujh R; Trehan A
    Pediatr Hematol Oncol; 2020 Oct; 37(7):610-619. PubMed ID: 32558608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults.
    Kushner BH; Meyers PA; Gerald WL; Healey JH; La Quaglia MP; Boland P; Wollner N; Casper ES; Aledo A; Heller G
    J Clin Oncol; 1995 Nov; 13(11):2796-804. PubMed ID: 7595741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial.
    Ladenstein R; Pötschger U; Le Deley MC; Whelan J; Paulussen M; Oberlin O; van den Berg H; Dirksen U; Hjorth L; Michon J; Lewis I; Craft A; Jürgens H
    J Clin Oncol; 2010 Jul; 28(20):3284-91. PubMed ID: 20547982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of chemotherapy cycles and intervals on outcomes of nonspinal Ewing sarcoma in adults: a real-world experience.
    Zhang J; Huang Y; Sun Y; He A; Zhou Y; Hu H; Yao Y; Shen Z
    BMC Cancer; 2019 Dec; 19(1):1168. PubMed ID: 31791278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l'Enfant.
    Oberlin O; Rey A; Desfachelles AS; Philip T; Plantaz D; Schmitt C; Plouvier E; Lejars O; Rubie H; Terrier P; Michon J;
    J Clin Oncol; 2006 Aug; 24(24):3997-4002. PubMed ID: 16921053
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of intermediate risk rhabdomyosarcoma and undifferentiated sarcoma with alternating cycles of vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide.
    Arndt CA; Nascimento AG; Schroeder G; Schomberg PJ; Neglia JP; Sencer SF; Silberman TL; Moertel CL; Tillisch JK; Miser JS
    Eur J Cancer; 1998 Jul; 34(8):1224-9. PubMed ID: 9849484
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose response and local control using radiotherapy in non-metastatic Ewing sarcoma.
    Paulino AC; Nguyen TX; Mai WY; Teh BS; Wen BC
    Pediatr Blood Cancer; 2007 Aug; 49(2):145-8. PubMed ID: 16732580
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
    Brennan B; Kirton L; Marec-Bérard P; Gaspar N; Laurence V; Martín-Broto J; Sastre A; Gelderblom H; Owens C; Fenwick N; Strauss S; Moroz V; Whelan J; Wheatley K
    Lancet; 2022 Oct; 400(10362):1513-1521. PubMed ID: 36522207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Favorable outcome of Ewing sarcoma family tumors to multiagent intensive preoperative chemotherapy: a single institution experience.
    Moschovi M; Trimis G; Stefanaki K; Anastasopoulos J; Syriopoulou V; Koultouki E; Tzortzatou-Stathopoulou F
    J Surg Oncol; 2005 Mar; 89(4):239-43. PubMed ID: 15726621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Feasibility of Treating Adults with Ewing or Ewing-Like Sarcoma with Interval-Compressed Vincristine, Doxorubicin, and Cyclophosphamide Alternating with Ifosfamide and Etoposide.
    Lu E; Ryan CW; Bassale S; Lim JY; Davis LE
    Oncologist; 2020 Feb; 25(2):150-155. PubMed ID: 32043790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extraskeletal Ewing's sarcoma family of tumors in adults: prognostic factors and clinical outcome.
    Tural D; Molinas Mandel N; Dervisoglu S; Oner Dincbas F; Koca S; Colpan Oksuz D; Kantarci F; Turna H; Selcukbiricik F; Hiz M
    Jpn J Clin Oncol; 2012 May; 42(5):420-6. PubMed ID: 22416252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli.
    Bacci G; Ferrari S; Bertoni F; Rimondini S; Longhi A; Bacchini P; Forni C; Manfrini M; Donati D; Picci P
    J Clin Oncol; 2000 Jan; 18(1):4-11. PubMed ID: 10623687
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vincristine, doxorubicin, cyclophosfamide, actinomycin D, ifosfamide, and etoposide in adult and pediatric patients with nonmetastatic Ewing sarcoma. Final results of a monoinstitutional study.
    Ferrari S; Palmerini E; Alberghini M; Staals E; Mercuri M; Barbieri E; Longhi A; Cantero L; Cesari M; Abate M; Balladelli A; Picci P; Bacci G
    Tumori; 2010; 96(2):213-8. PubMed ID: 20572576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.